Fig. 1: F. nucleatum and chemotherapy response in clinical samples.

Representative findings (a CT, PET, b pathology) in ESCC patients with favourable therapeutic effect. c, d Chemotherapeutic response rate according to F. nucleatum status using c SUV max response and d tumour regression grade. e The relationship between F. nucleatum DNA amount in pre-treatment biopsy specimens and RECIST.